Shares of other companies:
May 1, 2024 Inflation Persistence: No Fed Rate Cuts in Sight
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
Amazon Q1 Earnings: Strong Value Proposition
May 1, 2024
3M Stock: Dividend Likely Cut In Half
May 1, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
SNY Stock News and Mentions of Sanofi Stocktwits
Updated: May 2, 2024 (11:06)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Sanofi Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Sanofi (SNY).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Sanofi stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Sanofi (SNY)
May 2, 2024 (19:49) / "Benzinga" (by Vandana Singh)
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation - Regeneron Pharmaceuticals ( NASDAQ:REGN )
On Thursday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted EPS of $9.55, down 5% Y/Y, missing the consensus of $10.10. The company reported sales of $3.15 billion, missing the consensus of $3.22 billion. First quarter 2024 revenues decreased by 1%.
In Article Trend: Neutral
May 2, 2024 (16:23) / "Al Jareeza" (by Andy Hirschfeld)
What is behind the insulin shortage in the US?
Skye Murphy, who is 22 years old, has lived with type 1 diabetes since she was 14. In the past month, she learned that there would be a 30-to-60-day delay in receiving her medication Humalog, an insulin drug made by Eli Lilly.
In Article Trend: Neutral
May 2, 2024 (15:14) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
In Article Trend: Neutral
May 2, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Regeneron ( REGN ) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
In Article Trend: Neutral
May 2, 2024 (13:15) / "GlobeNewswire" (by Aprea Therapeutics)
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation ...
In Article Trend: Neutral
May 2, 2024 (13:15) / "Benzinga" (by Globe Newswire)
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Aprea Therapeutics ( NASDAQ:APRE )
DOYLESTOWN, Pa., May 02, 2024 ( GLOBE NEWSWIRE ) -- Aprea Therapeutics, Inc. APRE ( "Aprea", or the "Company" ) , a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q.
In Article Trend: Neutral
May 2, 2024 (11:15) / "Motley Fool" (by Prosper Junior Bakiny)
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
It pays to develop novel medicines for life-threatening illnesses.
In Article Trend: Somewhat-Bullish
May 2, 2024 (11:00) / "GlobeNewswire" (by Kymera Therapeutics)
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
KT-474/SAR444656 ( IRAK4 ) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of ...
In Article Trend: Neutral
May 2, 2024 (10:30) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
Regeneron Reports First Quarter 2024 Financial and Operating Results
TARRYTOWN, N.Y., May 02, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the first quarter of 2024 and provided a business update.
In Article Trend: Somewhat-Bullish
May 2, 2024 (09:04) / "Business Standard" (by Capital Market)
Indices trade with limited gains; Pharma shares advance
Indices trade with limited gains. Pharma shares advance Business Standard ...
In Article Trend: Somewhat-Bullish
May 2, 2024 (05:00) / "Benzinga" (by Globe Newswire)
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus ( nirsevimab ) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no ...
In Article Trend: Neutral
May 2, 2024 (05:00) / "GlobeNewswire" (by Sanofi - Aventis Groupe)
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations ...
In Article Trend: Neutral
May 1, 2024 (15:10) / "Zacks Commentary" (by Zacks Equity Research)
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
In Article Trend: Somewhat-Bullish
April 30, 2024 (14:31) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Benzinga's options scanner has just identified more than 16 option transactions on Regeneron Pharmaceuticals REGN, with a cumulative value of $427,360. Concurrently, our algorithms picked up 14 puts, worth a total of 418,490.
In Article Trend: Neutral
April 30, 2024 (13:00) / "Benzinga" (by Globe Newswire)
Mod Op Expands Its Full-Service Offerings with the Acquisition of LAM Design
NEW YORK, April 30, 2024 ( GLOBE NEWSWIRE ) -- Mod Op, a full-service digital marketing agency accelerating customer growth through human creativity, data science and innovation, today announced the acquisition of New York-based, brand strategy, package design & integrated marketing agency, LAM ...
In Article Trend: Bullish
April 30, 2024 (12:47) / "Zacks Commentary" (by Zacks Equity Research)
Should You Consider Regeneron ( REGN ) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
In Article Trend: Somewhat-Bullish
)
April 30, 2024 (12:28) / "Business Standard" (by Aneeka Chatterjee)
Sanofi India introduces diabetes drug 'Soliqua' at Rs 1,850 per pen
Sanofi India has introduced its latest diabetes treatment, Soliqua, following approval from the Central Drugs Standard Control Organisation ( CDSCO ) last year. Soliqua is a once-daily injectable blend of insulin glargine 100 Units/ml, a long-acting basal insulin, and lixisenatide, a GLP-1 ...
In Article Trend: Neutral
April 29, 2024 (11:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
EYLEA® HD ( aflibercept ) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases Long-term data and subgroup analyses from pivotal EYLEA HD clinical ...
In Article Trend: Neutral
April 26, 2024 (19:15) / "Motley Fool" (by Motley Fool Transcribing)
AbbVie ( ABBV ) Q1 2024 Earnings Call Transcript
ABBV earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 26, 2024 (15:34) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
In Article Trend: Somewhat-Bullish
April 25, 2024 (21:31) / "PR Newswire" (by LLP)
Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsight
The increasing occurrence of kidney disorders worldwide and the healthcare sector's increased focus on consistent monitoring and effective management of these conditions are expected to drive the demand for urine output monitoring systems between 2024 and 2030.
In Article Trend: Somewhat-Bullish
April 25, 2024 (18:27) / "PR Newswire" (by BioNJ)
BioNJ Announces Lineup for BioPartnering Conference
TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City. Sponsored by J.P.
In Article Trend: Bullish
April 25, 2024 (17:58) / "Benzinga" (by Vandana Singh)
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study - AbbVie ( NYSE:ABBV ) , Regeneron Pharmaceuticals ( NASDAQ:REGN )
Thursday, AbbVie Inc ABBV released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib ( Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response ) versus dupilumab ( Dupixent, per its labeled dose ) for ...
In Article Trend: Neutral
April 25, 2024 (17:47) / "Zacks Commentary" (by Zacks Equity Research)
AstraZeneca ( AZN ) Q1 Earnings & Sales Beat Estimates, Stock Up
AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
In Article Trend: Neutral
April 25, 2024 (17:45) / "Motley Fool" (by Motley Fool Transcribing)
Sanofi ( SNY ) Q1 2024 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (16:30) / "Motley Fool" (by Motley Fool Transcribing)
AstraZeneca Plc ( AZN ) Q1 2024 Earnings Call Transcript
AZN earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (15:19) / "Zacks Commentary" (by Zacks Equity Research)
Sanofi ( SNY ) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.
In Article Trend: Neutral
April 25, 2024 (14:15) / "Benzinga" (by Avi Kapoor)
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday - Carrier Global ( NYSE:CARR ) , AstraZeneca ( NASDAQ:AZN )
U.S. stocks were lower, with the Dow Jones falling over 600 points on Thursday. Shares of Sanofi SA SNY rose sharply during Thursday's session following better-than-expected first-quarter earnings. Sanofi reported first-quarter operating income of 2.8 billion euros, down 14.7% Y/Y and 4.2% on ...
In Article Trend: Bullish
April 25, 2024 (13:47) / "Benzinga" (by Vandana Singh)
Why Is Sanofi Shares Trading On Thursday? - Sanofi ( NASDAQ:SNY )
Thursday, Sanofi SA SNY reported first-quarter operating income of 2.8 billion euros, down 14.7% Y/Y and 4.2% on constant currency. The French drugmaker reported adjusted EPS of $0.97 ( 1.78 euros ) , beating the consensus estimate of $0.94.
In Article Trend: Somewhat-Bullish
April 25, 2024 (11:31) / "Investors Business Daily" (by Investor's Business Daily)
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca, Sanofi Jump On First-Quarter Earnings. Bristol Myers Lags Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Mammoth's proprietary ultracompact CRISPR-based gene editing platform and Regeneron's proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types TARRYTOWN, N.Y., April 25, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
In Article Trend: Somewhat-Bullish
April 25, 2024 (10:17) / "Benzinga" (by Shanthi Rexaline)
Meta, IBM Drag Nasdaq Futures Lower: What's Driving Premarket Action - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.'s META lukewarm second-quarter revenue guidance and commentary regarding investment punctured the stock, while International Business Machines Corp.
In Article Trend: Neutral
April 25, 2024 (05:30) / "GlobeNewswire" (by Sanofi - Aventis Groupe)
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (05:30) / "Benzinga" (by Globe Newswire)
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Sales growth of 6.7% at CER and business EPS ( 1 ) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024 Pharma launches up 90.5% to €606 million, led by Nexviazyme and ...
In Article Trend: Bullish
April 25, 2024 (04:59) / "GlobeNewswire" (by Dassault Systemes SE)
Dassault Systèmes Reports Solid First Quarter Results And Reaffirms Full-Year Objectives
Press Release ...
In Article Trend: Somewhat-Bullish
)
April 24, 2024 (16:57) / "Business Standard" (by Sohini Das)
Polio vax supplies: Health secy visits OPV maker Bilthoven's Dutch plant
As the country focuses on ensuring a secure supply of oral polio vaccines ( OPV ) , the Union health secretary visited the manufacturing unit of Bilthoven Biologicals at Utrecht, Netherlands, an arm of the Pune-based Serum Institute of India that manufactures OPV, on Wednesday.
In Article Trend: Neutral
April 24, 2024 (14:05) / "GlobeNewswire" (by Inc.)
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with ...
In Article Trend: Neutral
April 24, 2024 (13:19) / "Zacks Commentary" (by Ahan Chakraborty)
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
In Article Trend: Somewhat-Bullish
April 23, 2024 (16:03) / "Zacks Commentary" (by Zacks Equity Research)
Sanofi ( SNY ) Rilzabrutinib Shows Benefit in Blood Disorder Study
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:58) / "Zacks Commentary" (by Zacks Equity Research)
AstraZeneca ( AZN ) to Report Q1 Earnings: Here's What to Expect
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
In Article Trend: Neutral
April 23, 2024 (05:00) / "Benzinga" (by Globe Newswire)
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia ( ITP ) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITP
In Article Trend: Neutral
April 23, 2024 (05:00) / "GlobeNewswire" (by Sanofi - Aventis Groupe)
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia ...
In Article Trend: Neutral
April 22, 2024 (21:54) / "GlobeNewswire" (by Inc.)
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy ( ASGCT )
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss ...
In Article Trend: Neutral
April 22, 2024 (15:00) / "Benzinga" (by Globe Newswire)
Probiotic Ingredients Market Size is expected to reach USD 7.48 billion by 2031, growing at a CAGR of 4.20%: Straits Research
New York, United States, April 22, 2024 ( GLOBE NEWSWIRE ) -- Probiotics are microorganisms consumed to enhance the function of the digestive system. These microorganisms, also known as beneficial or healthy bacteria, prevent oral health conditions, bacterial vaginosis, and urinary tract ...
In Article Trend: Somewhat-Bullish
April 21, 2024 (21:45) / "Benzinga" (by Shanthi Rexaline)
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
As the market runs into rough weather, the importance of the upcoming week's earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. TSLA, Meta Platforms, Inc. META, Microsoft Corp. MSFT and Alphabet, Inc. GOOGL ( GOOG ) .
In Article Trend: Neutral
April 21, 2024 (11:41) / "Associated Press" (by WILL WEISSERT)
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It's not that clear-cut
What the cost of insulin may mean for Biden's campaign The Associated Press ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:15) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
In Article Trend: Neutral
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry - Regeneron Pharmaceuticals ( NASDAQ:REGN )
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals REGN against its key competitors in the ...
In Article Trend: Neutral
April 18, 2024 (11:00) / "Investors Business Daily" (by MOREY STETTNER)
How Ewing Kauffman Built A Pharma Giant
A few years after Ewing Kauffman launched Marion Laboratories in 1950, his sales manager urged him to invest $15,000 on an idea to gain business. Kauffman doubted the investment would pay off.
In Article Trend: Somewhat-Bullish
April 17, 2024 (18:39) / "Benzinga" (by Vandana Singh)
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick - AstraZeneca ( NASDAQ:AZN ) , Amgen ( NASDAQ:AMGN )
Tuesday, Amgen Inc AMGN provided an update regarding the results of the Phase 2a COURSE trial for Tezspire ( tezepelumab-ekko ) in chronic obstructive pulmonary disease ( COPD ) . Tezspire is a registered trademark of Amgen and AstraZeneca Plc AZN.
In Article Trend: Somewhat-Bullish
April 17, 2024 (15:48) / "Benzinga" (by Vandana Singh)
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years - Novartis ( NYSE:NVS )
Novartis AG NVS released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ( ofatumumab ) treatment for up to six years in recently diagnosed relapsing multiple sclerosis.
In Article Trend: Neutral
April 17, 2024 (15:37) / "Benzinga" (by Vandana Singh)
Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity - Sanofi ( NASDAQ:SNY )
Sanofi SA SNY reported Wednesday new data from a Phase 2 study in relapsing multiple sclerosis. What Happened: The company's CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. It also demonstrated favorable tolerability after nearly one year in participants with ...
In Article Trend: Neutral
April 17, 2024 (12:30) / "Benzinga" (by Globe Newswire)
IGM Biosciences Announces Refocusing of Sanofi Collaboration - IGM Biosciences ( NASDAQ:IGMS )
MOUNTAIN VIEW, Calif., April 17, 2024 ( GLOBE NEWSWIRE ) -- IGM Biosciences, Inc.
In Article Trend: Neutral
April 17, 2024 (12:30) / "GlobeNewswire" (by IGM Biosciences)
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with Sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases Agreement focuses on immunology/inflammation, aligning with Sanofi's ongoing commitment to advancing therapies for patients across ...
In Article Trend: Neutral
April 17, 2024 (05:00) / "Benzinga" (by Globe Newswire)
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis
In Article Trend: Neutral
April 17, 2024 (05:00) / "GlobeNewswire" (by Sanofi - Aventis Groupe)
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis ...
In Article Trend: Neutral
April 16, 2024 (22:30) / "PR Newswire" (by BrainStorm Cell Therapeutics Inc.)
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of ... PR ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (18:00) / "Canada Newswire" (by Sanofi-Aventis Canada Inc.)
Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by 50%
Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto ... Canada ...
In Article Trend: Bullish
April 12, 2024 (18:05) / "GlobeNewswire" (by Sanofi - Aventis Groupe)
Sanofi: Information concerning the total number of voting rights and shares - March 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce ( the French Commercial Code ) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers ( Regulation of the French stock market ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (14:40) / "Benzinga" (by Vandana Singh)
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee ( PRAC ) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists ( GLP-1 ) and suicidal or self-injurious thoughts and behaviors.
In Article Trend: Somewhat-Bearish
April 10, 2024 (18:42) / "Benzinga" (by Vandana Singh)
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says - Vaxcyte ( NASDAQ:PCVX )
The global market study pneumococcal conjugate ( PCV ) market is ~$8 billion per year, and Vaxcyte Inc PCVX estimates it will grow to ~$12 billion in the next few years. The market is currently split into 25% adults / 75% infants.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
Nurix ( NRIX ) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
In Article Trend: Neutral
April 10, 2024 (13:26) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer's ( PFE ) RSV Vaccine Study in Adults Under 60 Meets Goal
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
In Article Trend: Somewhat-Bullish
April 10, 2024 (11:00) / "GlobeNewswire" (by Nurix Therapeutics)
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences ...
In Article Trend: Neutral
April 9, 2024 (21:41) / "PR Newswire" (by DelveInsight Business Research)
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (15:15) / "Business Insider"
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited ( NYSE:BB ) rose sharply during Tuesday's session.
In Article Trend: Neutral
April 9, 2024 (14:43) / "Benzinga" (by Avi Kapoor)
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday - BlackBerry ( NYSE:BB ) , Tesla ( NASDAQ:TSLA )
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited BB rose sharply during Tuesday's session. The company announced a collaboration with Advanced Micro Devices, Inc.
In Article Trend: Neutral
April 9, 2024 (11:45) / "PR Newswire" (by Manasquan Bank)
Manasquan Bank Appoints Andrew Drechsler to Board of Directors
WALL TOWNSHIP, N.J., April 9, 2024 /PRNewswire/ -- Manasquan Bank is proud to announce the appointment of Andrew Drechsler to its Board of Directors, effective April 24, 2024. Mr. Drechsler is an accomplished financial and operational executive with extensive experience in both public and private ...
In Article Trend: Bullish
April 9, 2024 (11:00) / "GlobeNewswire" (by Inc.)
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation ...
In Article Trend: Neutral
April 8, 2024 (14:27) / "PR Newswire"
The first press conference with cats was held in Colombia - PR Newswire
The first press conference with cats was held in Colombia PR ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (08:28) / "Business Insider" (by markets.businessinsider.com)
OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
In Article Trend: Somewhat-Bullish
April 8, 2024 (05:42) / "The Financial Express" (by Health Desk)
Sanofi's new polio vaccine gets nod in India amid speculations of potential shortage
French drugmaker Sanofi has obtained approval for IMOVAX-Polio, an alternative injectable vaccine. According to a report by PTI, this new vaccine will replace the Inactivated Polio Vaccine ( IPV ) ShanIP in India.
In Article Trend: Somewhat-Bullish
April 7, 2024 (20:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration ( FDA ) and European Medicines Agency ( EMA ) Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration ( FDA ) and European Medicines Agency ( ...
In Article Trend: Neutral
April 7, 2024 (09:08) / "The Financial Express" (by FE Online)
Sanofi outlines India growth strategy; plans new launches, collaboration
Sanofi outlines India growth strategy. plans new launches, collaboration The Financial Express ...
In Article Trend: Somewhat-Bullish
)
April 7, 2024 (06:30) / "Business Standard" (by Press Trust of India)
Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline
Hrosz noted that Sanofi has a pipeline of 12 different products lined up for launch in the country
In Article Trend: Somewhat-Bullish
April 5, 2024 (17:41) / "CNN"
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts | Business
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts ...
In Article Trend: Neutral
April 5, 2024 (15:02) / "PR Newswire" (by 360iResearch)
Antacids Market Projected to Reach $10.18 billion by 2030 - Exclusive Report by 360iResearch
PUNE, India, April 5, 2024 /PRNewswire/ -- The report titled "Antacids Market by Drug Class ( Acid Neutralizers, H2 Antagonist, Promotility Agents ) , Formulation ( Liquid, Powder, Tablet ) , Indication, Distribution Channel - Global Forecast 2024-2030" is now available on 360iResearch.com's ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (08:05) / "Motley Fool" (by James Brumley)
3 Stocks to Consider Adding to Your Retirement Portfolio in April
Use the recent short-term weakness from these powerhouse companies' stocks to your advantage.
In Article Trend: Somewhat-Bullish
April 5, 2024 (07:09) / "Business Standard" (by Capital Market)
Benchmarks trade with tiny losses; VIX climbs 3.31%
Benchmarks trade with tiny losses. VIX climbs 3.31% Business Standard ...
In Article Trend: Neutral
)
April 4, 2024 (16:14) / "Business Standard" (by Sohini Das)
SII prepares to supply India's entire IPV requirement in 3-4 months
Serum Institute of India ( SII ) on Thursday said it can ramp up supplies to meet India's entire annual demand of the injectable inactivated poliomyelitis vaccines ( IPV ) within three to four months.
In Article Trend: Neutral
April 4, 2024 (13:56) / "CNBC" (by Annika Kim Constantino)
Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
The drug, made by Sanofi, is a GLP-1 like Novo Nordisk's blockbuster diabetes injection Ozempic and weight loss counterpart ...
In Article Trend: Neutral
April 4, 2024 (13:50) / "UPI Business"
Ozempic-like drug may slow Parkinson's, small study shows - .com
Ozempic-like drug may slow Parkinson's, small study shows UPI News ...
In Article Trend: Neutral
April 4, 2024 (13:16) / "Benzinga" (by Vandana Singh)
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster - Sanofi ( NASDAQ:SNY )
Sanofi SA SASY has announced an agreement in principle to settle approximately 4,000 lawsuits in the United States linked to the discontinued heartburn drug Zantac. The company stated that the settlement encompasses many pending cases across various U.S. state courts, excluding Delaware.
In Article Trend: Neutral
April 4, 2024 (12:45) / "Benzinga" (by Globe Newswire)
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
STUDIO CITY, Calif., April 04, 2024 ( GLOBE NEWSWIRE ) -- At the conclusion of this year's Myeloma Action Month, the International Myeloma Foundation ( IMF ) was truly grateful and overwhelmed by everyone's support in making the annual campaign a global success -with over 52 million reached in ...
In Article Trend: Bullish
April 4, 2024 (05:02) / "Business Standard" (by Capital Market)
Market erase early gains; pharma shares decline
Market erase early gains. pharma shares decline Business Standard ...
In Article Trend: Neutral
April 3, 2024 (16:09) / "GlobeNewswire" (by AB Science)
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
PRESS RELEASE ...
In Article Trend: Neutral
April 3, 2024 (12:00) / "Canada Newswire" (by BioVaxys Technology Corp.)
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International ... Canada ...
In Article Trend: Neutral
April 2, 2024 (14:40) / "Benzinga" (by Globe Newswire)
Cytokine Market Size is projected to reach USD 148.56 billion by 2031, growing at a CAGR of 8.40%: Straits Research
New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- A cytokine is a collection of proteins, peptides, or glycoproteins released by particular cells to regulate the development and function of the immune system and blood cells.
In Article Trend: Neutral
April 2, 2024 (04:30) / "GlobeNewswire" (by HUTCHMED (China) Limited)
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
- NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July ...
In Article Trend: Neutral
April 1, 2024 (07:30) / "Business Standard" (by Capital Market)
Sanofi India Ltd up for five straight sessions
Sanofi India Ltd is quoting at Rs 8151.5, up 0.46% on the day as on 12:44 IST on the NSE. The stock is up 40.71% in last one year as compared to a 29.18% gain in NIFTY and a 58.96% gain in the Nifty Pharma. Sanofi India Ltd is up for a fifth straight session in a row.
In Article Trend: Somewhat-Bullish
March 31, 2024 (23:00) / "GlobeNewswire" (by Curative Biotechnology)
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 ( GLOBE NEWSWIRE ) -- Curative Biotechnology Inc. ( OTC: CUBT ) ( "Curative Biotech" or the "Company" ) , a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the nomination to ...
In Article Trend: Somewhat-Bullish
March 29, 2024 (22:45) / "PR Newswire" (by Research and Markets)
Global Infectious Enteritis Treatment Market Report 2024: A USD$937.7 Million Market by 2034 - Antibiotics Segment Dominates the Market
Global Infectious Enteritis Treatment Market Report 2024: A USD$937.7 Million Market by 2034 - Antibiotics Segment ... PR ...
In Article Trend: Somewhat-Bullish
March 29, 2024 (11:11) / "The Atlantic" (by Katherine J. Wu)
The CDC Is Squandering a Breakthrough Vaccine
Protecting Babies Against RSV Is Still Too Hard The Atlantic ...
In Article Trend: Neutral
March 28, 2024 (17:45) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals REGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
March 28, 2024 (15:38) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Posts Pipeline Progress, Secures Blackstone Funding
Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.
In Article Trend: Neutral
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Denali Therapeutics ( DNLI ) Up 2.8% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 28, 2024 (12:00) / "Motley Fool" (by Prosper Junior Bakiny)
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:30) / "PR Newswire" (by DarioHealth Corp.)
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. ( Nasdaq: DRIO ) ( "Dario" or the "Company" ) , a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
In Article Trend: Neutral
March 28, 2024 (10:30) / "PR Newswire" (by DarioHealth Corp.)
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. ( Nasdaq: DRIO ) ( "Dario" or the "Company" ) , a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
In Article Trend: Neutral
March 28, 2024 (08:21) / "Business Standard" (by Capital Market)
Dr Reddy's rises on distribution partnership with Sanofi Healthcare
Dr Reddy's Laboratories gained 1.93% to Rs 6164.10 after the company said that it has entered into an exclusive partnership with Sanofi Healthcare India ( SHIPL ) to promote and distribute SHIPL vaccine brands across private markets in India. There is no upfront payment involved in this ...
In Article Trend: Bullish
March 28, 2024 (07:00) / "GlobeNewswire" (by INVENTIVA)
Inventiva announces the nomination of Andre Turenne as Director
Daix ( France ) , Long Island City ( New York, United States ) , March 28, 2024 - Inventiva ( Euronext Paris and Nasdaq: IVA ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic ...
In Article Trend: Neutral
March 28, 2024 (07:00) / "Benzinga" (by Globe Newswire)
Inventiva announces the nomination of Andre Turenne as Director - Inventiva ( OTC:IVEVF ) , Inventiva ( NASDAQ:IVA )
Daix ( France ) , Long Island City ( New York, United States ) , March 28, 2024 - Inventiva IVA ( the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ( ...
In Article Trend: Neutral
March 28, 2024 (04:09) / "Business Standard" (by Capital Market)
Market opens on firm note; breadth strong
Market opens on firm note. breadth strong Business Standard ...
In Article Trend: Neutral
March 28, 2024 (04:06) / "Money Control"
Dr Reddy's gains on distribution tie-up with Sanofi Healthcare
Dr Reddy's Laboratories | A meeting of the board of directors of the company will be held on Tuesday, May 7, 2024, to consider and approve the audited standalone and consolidated financial results of the company.
In Article Trend: Bullish
)
March 28, 2024 (03:12) / "Business Standard" (by Reuters)
J&J can contest evidence linking its talc to ovarian cancer, says US judge
Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S.
In Article Trend: Neutral
)
March 28, 2024 (02:24) / "Business Standard" (by Shivam Tyagi)
Stocks to watch: Maruti Suzuki, NHPC, Dr Reddy's, Biocon, REC, GOCL Corp
Stocks to watch on March 28: The Indian benchmark indices are looking at volatile start yet again on Thursday tracking uneven global trends. At 07:30 AM, the Gift Nifty futures were up 5 points against the Nifty 50 futures at 22,172.
In Article Trend: Somewhat-Bullish
March 27, 2024 (17:42) / "Benzinga" (by Vandana Singh)
What's Going With AstraZeneca Stock Trading Higher Today? - AstraZeneca ( NASDAQ:AZN )
Wednesday, Japan approved AstraZeneca Plc AZN and Sanofi SA's SNY Beyfortus ( nirsevimab ) , a long-acting monoclonal antibody for the prophylaxis of lower respiratory tract disease ( LRTD ) caused by respiratory syncytial virus ( RSV ) in all neonates, infants and children.
In Article Trend: Neutral
March 27, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Posts Upbeat Data From Next-Gen COVID Jab Study
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
In Article Trend: Neutral
March 27, 2024 (15:45) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Sanofi? - Sanofi ( NASDAQ:SNY )
Sanofi's SNY short percent of float has fallen 21.74% since its last report. The company recently reported that it has 4.54 million shares sold short, which is 0.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.53 days to cover their ...
In Article Trend: Somewhat-Bullish
)
March 27, 2024 (14:11) / "Business Standard" (by Sohini Das)
Open to acquisitions in oncology, obesity and other niche areas: Cipla
Mumbai-based Cipla is evaluating acquisition opportunities in oncology, mental health, obesity, wellness, genomics, and diagnostic services, a senior company official said.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:11) / "Business Standard" (by Sohini Das)
Big plans ahead: Cipla looks for shot in the arm in niche areas
Open to acquisitions in oncology, obesity and other niche areas: Cipla Business Standard ...
In Article Trend: Somewhat-Bullish
)
March 27, 2024 (11:15) / "Business Standard" (by Anjali Singh)
Dr Reddy's partners with Sanofi India to distribute vaccine brands in India
Dr Reddy's Laboratories has entered into an exclusive distribution partnership with Sanofi Healthcare India to promote and distribute their vaccine brands across private markets in India. This partnership aims to expand the availability of Sanofi's paediatric and adult vaccine brands within ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (09:00) / "GlobeNewswire" (by XORTX Therapeutics Inc.)
XORTX Announces New Clinical Advisory Board Member
CALGARY, Alberta, March 27, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ ) , a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease ( ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (09:00) / "Benzinga" (by Globe Newswire)
XORTX Announces New Clinical Advisory Board Member - XORTX Therapeutics ( NASDAQ:XRTX )
CALGARY, Alberta, March 27, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) XRTXXRTXANUA ) ) , a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease ( "ADPKD" ) , is pleased to announce that ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (07:35) / "Business Standard" (by Capital Market)
Sanofi India Ltd gains for third straight session
Sanofi India Ltd is quoting at Rs 7961.05, up 3.28% on the day as on 12:49 IST on the NSE. The stock is up 41.47% in last one year as compared to a 30.71% jump in NIFTY and a 58.88% jump in the Nifty Pharma index. Sanofi India Ltd is up for a third straight session today.
In Article Trend: Somewhat-Bullish
March 27, 2024 (04:11) / "Money Control"
Cipla, Sanofi India shares gain on distribution agreement
Cipla will be responsible for the distribution of Sanofi India's six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (04:03) / "The Financial Express" (by FE Business)
Sanofi, Cipla enters into exclusive distribution partnership to expand reach of CNS portfolio in India
Sanofi India Limited and Sanofi Healthcare India Private Limited ( together referred as Sanofi India ) and Cipla Limited announced an exclusive partnership for distribution and promotion of Sanofi India's Central Nervous System ( CNS ) product range in India.
In Article Trend: Somewhat-Bullish
March 27, 2024 (02:25) / "Business Standard" (by SI Reporter)
Stock Market LIVE: Sensex gains 250 pts, Nifty atop 22,050; RIL up 2%
Stock Market LIVE: Asian shares display mixed trend after US finishes lower Business Standard ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (02:10) / "Business Standard" (by Shivam Tyagi)
Stocks to watch on March 27: Aster DM, Adani Ports, CDSL, SpiceJet, L&T
Stocks to watch on March 27: The Indian bourses are looking at volatile beginning on Wednesday tracking mixed global cues. The Gift Nifty futures too suggest a likely tepid start at 07:00 AM, the futures were down 41 points against the Nifty 50 futures at 22,047.
In Article Trend: Neutral
March 27, 2024 (00:33) / "Money Control"
Buzzing Stocks: Aster DM, IIFL Finance, CDSL, Shyam Metalics and others in news
Stocks to watch: Check out the companies making headlines before the opening bell today, on March 27, 2024.
In Article Trend: Neutral
March 26, 2024 (18:50) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patients
Three drugmakers are capping out-of-pocket costs for their inhalers. Meanwhile, many digital diabetes management tools aren't all they're cracked up to be.
In Article Trend: Neutral
March 26, 2024 (17:11) / "Business Standard" (by Anjali Singh)
Sanofi, Cipla join hands to expand reach of CNS portfolio in India
Sanofi India and Cipla announced on Tuesday an exclusive partnership to boost access to Sanofi's Central Nervous System ( CNS ) medications across India. Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug.
In Article Trend: Somewhat-Bullish
March 26, 2024 (07:30) / "GlobeNewswire" (by Umicore)
Umicore - Notice of ordinary and special shareholders' meetings
Notice of ordinary and special shareholders' meetings ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (20:15) / "PR Newswire" (by Q32 Bio)
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
-- Q32 Bio to focus on advancement of bempikibart ( ADX-914 ) in ongoing atopic dermatitis ( AD ) and alopecia areata ( AA ) Phase 2 clinical trials and commencement of ADX-097 Phase 2 renal basket clinical trial in patients with complement disorders --
In Article Trend: Somewhat-Bullish
March 25, 2024 (11:30) / "Benzinga" (by Globe Newswire)
Dyne Therapeutics Announces CEO Transition - Dyne Therapeutics ( NASDAQ:DYN )
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
In Article Trend: Somewhat-Bullish
March 25, 2024 (11:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
Regeneron Provides Update on Biologics License Application for Odronextamab
TARRYTOWN, N.Y., March 25, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration ( FDA ) has issued Complete Response Letters ( CRLs ) for the Biologics License Application ( BLA ) for odronextamab in ...
In Article Trend: Neutral
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (14:30) / "Motley Fool" (by Adam Spatacco)
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:45) / "GlobeNewswire" (by Inc.)
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Palm Beach Gardens, FL, March 22, 2024 ( GLOBE NEWSWIRE ) -- Curative Biotechnology Inc. ( OTC: CUBT ) ( "Curative Biotech" or the "Company" ) , a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the nomination to its Board of ... Dr.
In Article Trend: Somewhat-Bullish
March 22, 2024 (06:30) / "Benzinga" (by Globe Newswire)
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
Availability of the Q1 2024 Memorandum for modelling purposes Paris, France - March 22, 2024. Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" page of the company's website:
In Article Trend: Neutral
March 20, 2024 (19:16) / "Benzinga" (by Benzinga Insights)
Regeneron Pharmaceuticals Unusual Options Activity For March 20 - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals REGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
March 20, 2024 (14:50) / "Benzinga" (by Globe Newswire)
Global Insulin Glargine Market Size is projected to reach USD 2200 million by 2031, growing at a CAGR of 6.11%: Straits Research
New York, United States, March 20, 2024 ( GLOBE NEWSWIRE ) -- Insulin glargine is a modified, long-acting form of medical insulin used to treat diabetes types I and II. It is subcutaneously injected. Typically, effects begin one hour following administration.
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:00) / "Canada Newswire"
2024 Sanofi Biogenius Canada Grants open for applications - Canada NewsWire
2024 Sanofi Biogenius Canada Grants open for applications Canada ...
In Article Trend: Bullish
March 19, 2024 (09:01) / "Business Standard" (by Capital Market)
Nifty below 22,850 mark; pharma shares decline
Nifty below 22,850 mark. pharma shares decline Business Standard ...
In Article Trend: Neutral
March 15, 2024 (20:01) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
March 15, 2024 (19:04) / "GlobeNewswire" (by Sanofi - Aventis Groupe)
Sanofi: Information concerning the total number of voting rights and shares - February 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce ( the French Commercial Code ) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers ( Regulation of the French stock market ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "PR Newswire" (by Research and Markets)
Prefilled Syringes Market, Industry Trends and Global Forecasts, 2035 - Surge in Dual Chamber Format Adoption Amid Growing Player Base
Prefilled Syringes Market, Industry Trends and Global Forecasts, 2035 - Surge in Dual Chamber Format Adoption Amid ... PR ...
In Article Trend: Neutral
March 14, 2024 (20:39) / "GlobeNewswire" (by CytoSorbents)
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
• STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 • CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration ( FDA ) and Health Canada this year
In Article Trend: Somewhat-Bullish
March 14, 2024 (17:55) / "GlobeNewswire" (by Euroapi France)
Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy
Paris - March 14th, 2024 - EUROAPI today announces that its Italian subsidiary, EUROAPI Italy S.R.L., is suspending the production of all APIs1 in Brindisi. Following an internal audit, quality control deficiencies due to potential local misconduct have been identified and are being further ...
In Article Trend: Neutral
March 14, 2024 (12:30) / "GlobeNewswire" (by MeiraGTx)
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (10:00) / "Benzinga" (by Globe Newswire)
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline - First Wave BioPharma ( NASDAQ:FWBI )
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer
In Article Trend: Somewhat-Bullish
March 14, 2024 (10:00) / "GlobeNewswire" (by First Wave BioPharma)
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (09:00) / "Benzinga" (by Globe Newswire)
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
DURHAM, United Kingdom and CAMBRIDGE, United Kingdom, March 14, 2024 ( GLOBE NEWSWIRE ) -- S. M. Discovery Group ( SMDG ) , a preclinical-stage company developing treatments for neurodegenerative diseases and rare pediatric disorders, announced today the appointment of Dr. Zsuzsanna Devecseri, ...
In Article Trend: Bullish
March 14, 2024 (03:58) / "Money Control"
Sanofi India inks distribution pact with Emcure, but shares trade flat
The share touched a 52-week high of Rs 9,370.35 and a 52-week low of Rs 5,329.70 on 23 February, 2024 and 03 May, 2023, respectively.
In Article Trend: Somewhat-Bullish
March 13, 2024 (17:32) / "Zacks Commentary" (by Zacks Equity Research)
NewAmsterdam ( NAMS ) Doses Patient in HeFH Study, Shares Up
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.
In Article Trend: Neutral
)
March 13, 2024 (13:12) / "Business Standard" (by Anjali Singh)
Sanofi India, Emcure Pharma announce exclusive distribution partnership
Sanofi India and Emcure Pharmaceuticals on Monday announced an exclusive distribution and promotion agreement for Sanofi's cardiovascular products in India. Effective immediately, Emcure Pharmaceuticals will exclusively distribute and promote Sanofi India's Cardiovascular brands including ...
In Article Trend: Bullish
March 13, 2024 (08:05) / "Business Standard" (by Capital Market)
Sanofi India Ltd eases for fifth straight session
Sanofi India Ltd is quoting at Rs 8017, down 3.84% on the day as on 13:19 IST on the NSE. The stock jumped 47.1% in last one year as compared to a 29.63% rally in NIFTY and a 60.88% spurt in the Nifty Pharma index. Sanofi India Ltd dropped for a fifth straight session today.
In Article Trend: Somewhat-Bullish
March 13, 2024 (07:00) / "GlobeNewswire" (by Faron Pharmaceuticals Oy)
Faron's Financial Statement Release January 1 to December 31, 2023
TURKU, Finland and BOSTON, March 13, 2024 ( GLOBE NEWSWIRE ) -- Faron Pharmaceuticals Ltd. ( "Faron" or "the Company" ) ( AIM: FARN, First North: FARON ) , a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, today announced ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:32) / "Zacks Commentary" (by Zacks Equity Research)
Regeneron ( REGN ) Gets FDA Nod for Praluent Label Extension
Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
In Article Trend: Neutral
March 12, 2024 (14:20) / "Benzinga" (by Globe Newswire)
Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research - Agile Therapeutics ( NASDAQ:AGRX ) , GSK ( NYSE:GSK )
New York, United States, March 12, 2024 ( GLOBE NEWSWIRE ) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases ( STDs ) , the transmission of sexually transmitted infections ( STIs ) , family planning, and birth control.
In Article Trend: Somewhat-Bullish
March 12, 2024 (13:58) / "Zacks Commentary" (by Zacks Equity Research)
ASLAN ( ASLN ) Up 161% on Upbeat Initial Data From Eczema Study
ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
In Article Trend: Neutral
March 12, 2024 (09:39) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.
In Article Trend: Somewhat-Bullish
March 11, 2024 (20:34) / "GlobeNewswire" (by Interpublic Group of Companies)
IPG Tops the 2024 Ad Age 'A-List'
The Martin Agency and The Weber Shandwick Collective Named to the ...
In Article Trend: Bullish
March 11, 2024 (14:38) / "Benzinga" (by Piero Cingari)
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' - AstraZeneca ( NASDAQ:AZN ) , ASML Holding ( NASDAQ:ASML )
Goldman Sachs has flagged an increasing concern over the U.S. stock market's heavy concentration and the dominant sway of its largest tech stocks, urging investors to broaden their geographical diversification.
In Article Trend: Neutral
March 11, 2024 (11:00) / "GlobeNewswire" (by FibroGen)
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
SAN FRANCISCO, March 11, 2024 ( GLOBE NEWSWIRE ) -- FibroGen, Inc. ( NASDAQ: FGEN ) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global ...
In Article Trend: Neutral
March 11, 2024 (11:00) / "GlobeNewswire" (by Inc.)
Praluent® ( alirocumab ) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia ( HeFH ) Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia ...
In Article Trend: Neutral
March 11, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and symptoms with amlitelimab for 28 weeks
In Article Trend: Neutral
March 11, 2024 (06:00) / "GlobeNewswire" (by Sanofi - Aventis Groupe)
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis ...
In Article Trend: Neutral
March 10, 2024 (17:00) / "Business Insider" (by markets.businessinsider.com)
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis ( PsA ) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic ... - Markets Insider ...
In Article Trend: Neutral
March 10, 2024 (16:00) / "GlobeNewswire" (by MoonLake Immunotherapeutics AG)
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis ( PsA ) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis ( PsA ) and other important updates at its R&D Day • Positive 24-week data from the ARGO trial of sonelokimab in PsA: • Significant improvements observed across all key outcomes, ...
In Article Trend: Neutral
March 8, 2024 (16:15) / "Benzinga" (by Benzinga Insights)
( SNY ) - Analyzing Sanofi's Short Interest - Sanofi ( NASDAQ:SNY )
Sanofi's SNY short percent of float has fallen 21.74% since its last report. The company recently reported that it has 4.54 million shares sold short, which is 0.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.53 days to cover their ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:15) / "Motley Fool" (by Prosper Junior Bakiny)
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
EYLEA® HD ( aflibercept ) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration ( wAMD ) and Diabetic Macular Edema ( DME ) Published in The Lancet
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA® ( aflibercept ) Injection 2 mg with fixed 8-week dosing in patients with wAMD and DME in the first year ...
In Article Trend: Neutral
March 8, 2024 (05:30) / "Motley Fool" (by Motley Fool Transcribing)
MacroGenics ( MGNX ) Q4 2023 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:00) / "Benzinga" (by Globe Newswire)
NodThera's NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson's Disease Phase Ib/IIa Trial
Brain-penetrant NLRP3 inflammasome inhibitor NT-0796 reduced key neuroinflammatory and inflammatory biomarkers in Parkinson's disease patients to the levels found in healthy elderly controls over 28 days Demonstrates potential to change the treatment paradigm and halt disease progression with a ...
In Article Trend: Neutral
March 7, 2024 (09:50) / "Benzinga" (by Globe Newswire)
Acinetobacter Pneumonia Therapeutics Market to Reach USD 927.1 Million to 2031
Jersey City, NJ, March 07, 2024 ( GLOBE NEWSWIRE ) -- InsightAce Analytic Pvt.
In Article Trend: Neutral
March 6, 2024 (21:36) / "The Atlantic" (by Jacob Stern)
He Got 49 COVID Shots in One Month!
On June 3, 2021, a roughly 60-year-old man in the riverside city of Magdeburg, Germany, received his first COVID vaccine. He opted for Johnson & Johnson's shot, popular at that point because unlike Pfizer's and Moderna's vaccines, it was one-and-done. But that, evidently, was not what he had in ...
In Article Trend: Neutral
March 6, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Encephalitis Treatment Market Overview 2024-2028: Expected Market Size, Major Growth Factors And Lucrative Segments As Per The Business Research Company's Encephalitis Treatment Global Market Report 2024
LONDON, March 06, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's encephalitis treatment global market report 2024, the encephalitis treatment market has exhibited robust growth in recent years, with a notable increase in market size.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:11) / "CNN" (by Mira Cheng)
A man deliberately got 217 Covid shots. Here's what happened
One German man has redefined "man on a mission." A 62-year-old from Magdeburg deliberately got 217 Covid-19 vaccine shots in the span of 29 months, according to a new study, going against national vaccine recommendations. That's an average of one jab every four days.
In Article Trend: Neutral
March 5, 2024 (21:55) / "Canada Newswire" (by 1290448 B.C. Ltd)
1290448 B.C. Ltd. Announces Binding Letter Agreement with SRx Health Solutions Inc. for Reverse Takeover Transaction
1290448 B.C. Ltd. Announces Binding Letter Agreement with SRx Health Solutions Inc. for Reverse Takeover ... Canada ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (08:15) / "PR Newswire" (by Thought Industries)
Thought Industries Continued EMEA Growth and Momentum Recognized by 2024 Fosway 9-Grid™
The Need For Extended Enterprise Learning Solutions in EMEA Continues to Grow as Companies Seek New Ways to Retain Customers and Diversify Revenue
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:00) / "GlobeNewswire" (by MoonLake Immunotherapeutics AG)
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting ...
In Article Trend: Neutral
March 4, 2024 (12:35) / "Benzinga" (by Globe Newswire)
Global Drug Discovery Outsourcing Market Size is Estimated to Reach USD 6370 million by 2030, Growing at a CAGR of 7.6%: Straits Research
New York, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- Outsourcing drug development is a method for discovering novel drugs or therapies in several pharmaceutical, pharmacology, and biochemistry domains. In addition, outsourcing drug discovery initiates the medication development process.
In Article Trend: Somewhat-Bullish
March 4, 2024 (12:10) / "Benzinga" (by Globe Newswire)
Osteoarthritis Drugs Market Expected to Hit USD 17.7 billion by 2031, Growing at a CAGR of 8.5%: Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global osteoarthritis drugs market is projected to rise at a CAGR of 8.5% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 17.7 billion is anticipated for the ...
In Article Trend: Neutral
Related stocks from Healthcare sector
Allied Healthcare Products, Inc. (AHPI)
Baxter International Inc. (BAX)
AN2 Therapeutics, Inc. (ANTX)
G1 Therapeutics, Inc. (GTHX)
Pacific Biosciences of California, Inc. (PACB)
Oramed Pharmaceuticals Inc. (ORMP)
Change Healthcare Inc. (CHNG)
PerkinElmer, Inc. (PKI)
Kiniksa Pharmaceuticals, Ltd. (KNSA)
Zynerba Pharmaceuticals, Inc. (ZYNE)
This website uses cookies to ensure you get the best experience on our website